New Evidence Confirms Safety and Efficacy of Lecanemab for Early-Stage Alzheimer’s
Recent studies reaffirm the safety and effectiveness of lecanemab in slowing Alzheimer’s progression, with rare manageable side effects observed in early-stage patients.
Lecanemab: A New Hope in Alzheimer’s Treatment
The FDA approved the drug lecanemab, marketed as Leqembi, in 2023 for treating Alzheimer’s disease. Recent real-world studies affirm its safety, showing that serious side effects like amyloid-related imaging abnormalities (ARIA) are rare and manageable, especially when used early.
Lecanemab is a type of antibody designed to target amyloid proteins in the brain, which form plaques associated with Alzheimer’s. Clinical trials have demonstrated that patients receiving lecanemab experienced a 25-30% slower decline in cognitive functions over 18 months compared to untreated groups. Imaging effects also showed reductions or clearance of amyloid plaques.
A new study published in JAMA Neurology involving 234 patients at Washington University observed that only 1.8% of those with very mild Alzheimer’s symptoms showed ARIA symptoms, compared to 27% in those with more advanced stages. Most ARIA cases were mild and resolved within months, with no fatalities.
Experts highlight that early diagnosis is crucial as early-stage patients benefit the most. Continued research aims to better identify individuals at higher risk of ARIA, to optimize treatment safety.
While lecanemab offers hope, physicians emphasize careful patient selection and monitoring to balance benefits against risks such as side effects and ARIA. Ongoing studies and real-world data will help refine these treatments and expand options for managing Alzheimer’s disease.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Safety and Effectiveness of GLP-1 Receptor Agonists for Obesity Treatment in Adults with Mental Illness
New evidence shows GLP-1 receptor agonists are safe and effective in promoting weight loss and improving metabolic health in adults with mental illness, with no increased risk of adverse psychiatric effects. These medications offer promising benefits for addressing obesity in this vulnerable population.
How Aggressive Breast Cancer Evades Immune Detection Through Lymph Node Changes
New research uncovers how aggressive breast cancer manipulates lymph nodes to evade immune detection, paving the way for novel therapies to prevent metastasis.
Innovative Four-Drug Regimen Sets New Standard for Treating Multiple Myeloma
A groundbreaking clinical trial introduces a new four-drug combination that significantly improves outcomes for patients with newly diagnosed multiple myeloma, establishing a fresh standard of care.
Cancer-Related Nerve Damage Contributes to Chronic Inflammation and Resistance to Immunotherapy
New research uncovers how nerve injury caused by cancer promotes chronic inflammation, leading to resistance against immunotherapy. Targeting nerve damage pathways may enhance treatment responses.